Results for the quarter ended 30.06.2024
Awaiting price reaction for this filing.
Sangam Health Care Products reported Q1 FY25 (quarter ended June 30, 2024) net sales of Rs. 339.18 lakhs, up 32.4% from Rs. 256.19 lakhs in the same quarter last year. The company swung from a loss of Rs. 69.04 lakhs in Q1 FY24 to a profit of Rs. 8.09 lakhs in Q1 FY25, marking a return to profitability. EPS improved from a loss of Rs. 0.46 to a positive Rs. 0.05 per share. The improvement was driven by strong revenue growth and lower employee benefit expenses (Rs. 54.66 lakhs vs Rs. 190.14 lakhs). Statutory auditors M M Reddy & Co. issued an unqualified limited review report with no qualifications or emphasis of matter.
Positive for shareholders — the company posted strong revenue growth and a return to profit after a year-ago loss, though the absolute profit remains thin and the company is small-cap with limited reserves. Investors should watch for sustained profitability in upcoming quarters.